Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus FOLFOX4 in advanced HCC
NCT03605706Phase 3
Key facts
- Status
- Unknown
- Start
- May 2019
- Primary completion
- Feb 2023
- Countries
- 1
- Sponsor
- Hengrui
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- camrelizumab
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Camrelizumab + FOLFOX4 with Placebo + FOLFOX4 (2 arms). Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Camrelizumab + FOLFOX4
Camrelizumab (SHR-1210) 3mg/kg IV D1 + FOLFOX4 (Oxaliplatin, Leucovorin, Fluorouracil) q2w
Placebo + FOLFOX4
Placebo IV D1 + FOLFOX4 (Oxaliplatin, Leucovorin, Fluorouracil) q2w
03
Who it enrols
Patients with advanced/metastatic HCC, no prior systemic treatment, Child-Pugh A or B7, and ECOG 0-1.
04
Endpoints
Primary
Overall Survival
Secondary
Objective Response Rate
Time to Progression
Duration of Response
Disease Control Rate
Progression-Free Survival
Adverse Events
Overall Survival Rate
Beyond the preview
Go deeper on NCT03605706.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605706.